Unknown PHASE3 INTERVENTIONAL NCT00141947

Bexarotene Treatment in Schizophrenia

Safety and Efficacy of Add-On Oral Bexarotene to Antipsychotic Treatment in Schizophrenia Patients: An Open Label Trial

Sponsor: Beersheva Mental Health Center

Updated 5 times since 2017 Last updated: Jul 23, 2013 Started: Sep 30, 2005 Completion: Sep 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00141947, this PHASE3 trial focuses on Schizophrenia and remains ongoing. Sponsored by Beersheva Mental Health Center, it has been updated 5 times since 2005, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beersheva Mental Health Center
Stanley Medical Research Institute

Data source: Beersheva Mental Health Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beersheva, Israel
• Hadera, Israel